Premium
Ex Vivo PKH26‐Labelling of Lymphocytes for Studies of Cell Migration In Vivo
Author(s) -
JOHNSSON C.,
FESTIN R.,
TUFVESON G.,
TÖTTERMAN T. H.
Publication year - 1997
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1046/j.1365-3083.1997.d01-430.x
Subject(s) - in vivo , fluorescein isothiocyanate , labelling , ex vivo , cell , spleen , chemistry , fluorescein , flow cytometry , biology , in vitro , microbiology and biotechnology , pathology , fluorescence , biochemistry , immunology , medicine , physics , quantum mechanics
A prerequisite for studies of cell migration is that the cells of interest can be appropriately labelled and subsequently easily traced. The use of radioisotopes or fluorescent substances that bind covalently to the cell surface, e.g. fluorescein isothiocyanate (FITC) or rhodamine isothiocyanate (RITC), have limitations such as rapid loss of the labelling, toxicity and interference with cell surface molecules. In the present work the authors labelled rat spleen lymphocytes with the fluorescent labelling molecule PKH26, which is incorporated into the lipid bilayer of cytoplasmic membranes. The labelled lymphocytes were injected intravenously into syngeneic recipients and 2 or 6 days later the lymphocytes were detected in various organs by using flow cytometry and fluorescence microscopy. As could be expected, the lymphocytes homed to lymphoid tissues, preferably the spleen, and no labelled cells were found in non‐lymphoid organs such as the heart and the kidney. Membrane labelling proved to be intense, uniform and stable and PKH26 positive cells were easily detectable in fractions less than 0.2% in peripheral blood and the various tissues after 6 days of in vivo circulation. Thus, the PKH26 dye appears to be suitable for labelling cell populations used in the study of cell migration in vivo , both under normal conditions and when specific immunological processes are taking place, such as graft rejection and tumour growth.